2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology

Inaugural Symposiums:
Immunotherapy of Prostate & GU Cancers and World Consortium on Advanced Prostate Cancer

SEPTEMBER 6-9, 2017 • NEW YORK CITY

Mount Sinai Hospital
Stern Auditorium
1468 Madison Avenue @ 100th Street
New York, NY 10029

Course Director
Ash Tewari, MBBS, MCh

Co–Director
Ketan K. Badani, MD

Associate Directors
Nina Bhardwaj, MD, PhD
Carlos Cordon-Cardo, MD, PhD
William Oh, MD

Site Directors
Mantu Gupta, MD
Michael A. Palese, MD

In collaboration with
Society of Urologic Robotic Surgeons and Endourological Society

Milton and Carroll Petrie Department of Urology
Icahn School of Medicine at Mount Sinai
Celebrating our Diamond Jubilee • 1942-2017
COURSE DESCRIPTION
The Mount Sinai Urology Department will host a live interactive state-of-the-art educational symposium. The program will include 3D demonstrations of the latest robotic surgery techniques for prostate, kidney and bladder cancer. Directed by the world’s leading robotic experts and taught by an internationally renowned faculty. Format includes point – counterpoint debates, didactic lectures and abstract presentations.

OBJECTIVES
At the conclusion of the course, participants should be able to:
• Utilize screening techniques for prostate cancer more efficiently to reduce the numbers of biopsies and diagnosis of clinically insignificant prostate cancer.
• Discuss effective management of treatment failure in prostate cancer to help reduce mortality.
• Describe the most recent approach to treating locally advanced and metastatic urologic disorders.
• Identify the technical challenges of robotic urologic oncologic surgery.

TARGET AUDIENCE
National and International Urologists, Urologic Surgeons, Urologic Oncologists, Mid-Level Providers

REGISTER ON-LINE: www.mountsinaiurologycme.org

REGISTRATION FEES
$625       MD, PhD
$250       Residents/Fellows
$150       Nurses, PAs and Allied Health Professionals
Mount Sinai faculty, residents, employees and voluntary faculty are eligible for scholarship, and must have a coupon code. Contact Carrie Brennan, Department of Urology for information at caroline.brennan@mountsinai.org

MEETING LOCATION
Mount Sinai Hospital
Stern Auditorium
1468 Madison Avenue @ 100th Street
New York, NY 10029

HOTEL ACCOMMODATIONS
A limited number of discounted rooms are available at:
Bentley Hotel
500 East 62nd Street
212-644-6000
http://bentleyhotelnyc.com

Courtyard by Marriott
410 East 92nd Street
212-410-6777

In order to book hotel accommodations in the Mount Sinai Urology Symposium discounted room block, please either contact the hotel directly, or you may book online on the symposium website: www.mountsinaiurologycme.org

ACCREDITATION
The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 26.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

VERIFICATION OF ATTENDANCE
Verification of attendance will be provided to all professionals.

SPECIAL NEEDS
The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend this conference and require any special needs or accommodations please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.

FACULTY DISCLOSURE
It is the policy of Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
AGENDA

WEDNESDAY, SEPTEMBER 6th

MOUNT SINAI HOSPITAL ATRIUM AND ANNENBERG 5-205

11:00–1:45  The Push Up for Prostate Cancer Challenge [Atrium]
1:45–2:00  Welcome Message From The Dean and Department Chair
2:00–2:20  The 75th Edition: Our Journey and Achievements  Michael J. Droller, MD
2:20–2:30  Residency Integration  Carl Olsson, MD
2:30–2:40  History of Voluntary Faculty at Mount Sinai  Alex Kirschenbaum, MD
2:40–2:55  My Personal Journey  Howard Schiff, MD
2:55–3:10  Elmhurst Affiliation With Mount Sinai  Hugh Lavery, MD
3:10–3:25  Stone Center  Mantu Gupta, MD
3:25–3:40  Men’s Health Program  Steven A. Kaplan, MD
3:40–3:55  Sexual Medicine  Robert Valenzuela, MD
3:55–4:10  Reconstructive Urology  Rajveer Purohit, MD
4:10–4:25  Transplant and Donor Nephrectomy Program  Michael A. Palese, MD
4:25–4:40  Intervention Urology  Ardeshir Rastinehad, DO
4:40–4:55  Robotic Surgery  Ketan K. Badani, MD
4:55–5:10  Pediatric Urology  Jeffrey Stock, MD
5:10–5:25  Bladder Cancer Program  Peter Wiklund, MD, PhD
5:25–5:35  Immunotherapy  Simon Hall, MD
5:35–5:45  Behavioral Research  Nihal Mohamed, PhD
5:45–5:55  New Adjuvant Platforms For Immunotherapy  Sujit Nair, PhD
5:55–6:05  Abdominal Inflammation and Prostate Cancer  Kamlesh Yadav, PhD
6:05–6:15  Residency at Mount Sinai  John Griffiths, MD
6:15–6:25  Close of Meeting  Ash Tewari, MBBS, MCh

THURSDAY, SEPTEMBER 7th

STERN AUDITORIUM

7:20–7:30  Welcome and Introduction  Ash Tewari, MBBS, MCh

SESSION I  SCREENING & LOW RISK DISEASE

Moderator: Peter Carroll, MD, MPH

7:30–8:00  THE HANS E. SCHAPIRA LECTURE

How Nerve Sparing Changed the Outcome of Prostate Cancer  Patrick Walsh, MD

8:00–9:00  Live Surgery

Surgeon: Ash Tewari, MBBS, MCh
Moderator: Ketan K. Badani, MD
Panel: Thomas Ahlering, MD, Giuseppe Carriero, MD, Michael A. Palese, MD

9:00–9:10  Epidemiology  Lorelei Mucci, MPH, ScD
9:10–9:25  Screening For Prostate Cancer  Fritz Schröder, MD
9:25–9:40  USPTF Recommendations  Jim Hu, MD, MPH
9:40–10:00  Genomic Complexity of Prostate Cancer  Ash Tewari, MBBS, MCh

Supported by Necdet Ersoy

10:00–10:20  Immunotherapy in Prostate Cancer  James Gulley, MD, PhD
10:20–10:40  BREAK / VISIT EXHIBITS
10:40–11:00  Emerging Role of MRI for Screening  Ash Tewari, MBBS, MCh
11:00–11:15  Emerging Role of Genomics  Leonard Gomella, MD
11:15–11:25  Novel Biomarkers  Badrinath Konety, MD, MBA
11:25–11:40  Active Surveillance  Peter Carroll MD, MPH
AGENDA

THURSDAY, SEPTEMBER 7th continued

11:40–12:00 DEBATE: Genomics vs. MRI in Risk Stratification
Moderator: Peter Carroll MD, MPH
Genomics: Eric Klein, MD
MRI: Ardeshir Rastinehad, DO

12:00–1:00 LUNCH SYMPOSIUM

1:00–2:00 Live Surgery
Surgeon: Ash Tewari, MBBS, MCh
Moderator: Vipul Patel, MD
Panel: Michael Herman, MD, Christopher Porter, MD, Ronney Abaza, MD

SESSION II FOCAL THERAPY
Moderator: Jörn Witt, MD

2:00–2:15 Prostate MRI: What Urologists Should Know
Bachir Taouli, MD

2:15–2:25 3D Mapping Biopsy
Nelson Stone, MD

2:25–2:40 Fusion Biopsy: Current Status and Future Directions
Peter Schulam, MD, PhD

2:40–2:50 Focal Therapy & Index Lesion
Dipen Parekh, MD

2:50–3:00 Focal Therapy: Is it Ready for Prime Time?
Herbert Lepor, MD

3:00–3:10 HIFU
Dipen Parekh, MD

3:10–3:20 Gold Nanoparticle Treatment
Ardeshir Rastinehad, DO

3:20–3:40 BREAK / VISIT EXHIBITS

SESSION III TREATMENT OF RECURRENCE
Moderator: John Davis, MD, FACS

3:40–3:50 Prevention of Positive Margins and BCR: Neurosafe
Alexander Haese, MD

3:50–4:00 Neurosafe: US Experience
Kenneth Haines, MD

4:00–4:15 Importance of Surgical Margins & Biochemical Failure
Michael Cookson, MD

4:15–4:25 Adjuvant vs. Salvage Treatment Post Radical Prostatectomy
John Davis, MD, FACS

4:25–4:35 Role of Salvage LND in Recurrence
Thomas Ahlering, MD

4:35–4:45 Focal Therapy Failure
Arnauld Villers MD, PhD

4:45–5:05 DEBATE: Radiotherapy Failure: Salvage RALP vs. Cryotherapy
Moderator: Ketan K. Badani, MD
RALP: Vipul Patel, MD
Cryotherapy: Aaron Katz, MD, FACS

5:05–5:15 Best Poster Award

5:15–5:30 BREAK / VISIT EXHIBITS

BREAKOUT ROOM – ANNENBERG 25-51

SESSION I IMMUNOTHERAPY & TUMOR MICROENVIRONMENT
Moderator: Nina Bhardwaj, MD, PhD

1:00–1:15 Dendritic Vaccine Platforms for Cancer Immunotherapy
Oncogenomics and Neo-antigen Discovery
Nina Bhardwaj, MD, PhD

1:15–1:30 Standard of Care and Combination Immunotherapy:
Understanding Therapeutic Synergy
Matthew Galsky, MD

1:30–1:45 Tumor Microenvironment and Immuno-engineering
Ankur Singh, PhD

1:45–2:00 High Throughput PhIP-Seq and Phase Display System –
Applications in Cancer Research and Immunotherapy
Uri Laserson, PhD

2:00–2:15 Biomarkers and Immunotherapy
Susan F. Slovin, MD, PhD

2:15–2:30 Next Generation Platforms for Immune Monitoring
Sacha Gnajatic, PhD

2:30–2:45 Success of Immunotherapy – Lessons Learned from
Inflamed and Noninflamed Cancers
Ash Tewari, MBBS, MCh

2:45–3:00 Immuno-Oncology's Signal-to-Noise Problem:
Developing Proof of Relevance for Novel MOAs
Jeffrey M. Bockman, PhD

3:00–3:30 BREAK / VISIT EXHIBITS
THURSDAY, SEPTEMBER 7th continued

SESSION II  BASIC SCIENCE SESSION
Moderators: Josep Domingo-Domenech, MD, PhD, Kamlesh Yadav, PhD, Veronica Rodriguez-Bravo, PhD, Shalini Singh-Yadav, PhD

3:30–3:45  Targetable Mechanisms of Aggressiveness in Lethal Prostate Cancer  Josep Domingo-Domenech, MD, PhD
3:45–4:00  Patient Centered Outcomes in Urologic Care: Limitations and Potential Solutions  Nihal Mohamed, PhD
4:00–4:15  Genome Integrity Maintenance Mechanisms In Prostate Cancer  Veronica Rodriguez-Bravo, PhD
4:15–4:30  Tumor Heterogeneity in Prostate and Kidney Cancer  Shalini Singh Yadav, PhD
4:30–4:45  Targeting Castration Resistant Metastatic Prostate Cancer with a Novel Glycolytic Pathway Inhibitor  Yixuan Gong, PhD
4:45–5:00  Novel Therapeutic Strategies for Neuroendocrine Prostate Cancer  Kamlesh Yadav, PhD
5:00–5:15  PI3K/PTEN Pathway Can Present a Vulnerability of Prostate Cancer  Sait Ozturk, PhD
5:15–5:30  Advanced Diffusion-Weighted Imaging of Prostate Cancer: Correlation with Quantitative Histopathology  Stefanie Hectors, PhD
5:30–5:45  Mechanism-Based Studies to Elucidate the Role of Tumor Antigens in Prostate Cancer  Sujit Nair, PhD

FRIDAY, SEPTEMBER 8th

SESSION I  RADICAL PROSTATECTOMY
Moderator: David Albala, MD, Inderbir Gill, MD

7:00–7:10  Surgical Anatomy of Prostate  Atsushi Takenaka, MD, PhD
7:10–7:20  Neural Supply of the Male Urethral Sphincter  Thomas Bessede, MD
7:20–7:40  Foundations of Anatomic RALP – Continence  Ash Tewari, MBBS, MCh
7:40–7:50  Radical Prostatectomy Technique for Preservation of Urinary Continence and the Pagano Suture  John Libertino, MD
7:50–8:00  Nerve Sparing Techniques  Vipul Patel, MD
8:00–9:00  Live Surgery
Surgeon: Ash Tewari, MBBS, MCh
Moderator: Thomas Ahlering, MD
Panel: Dipen Parekh, MD, John Davis, MD, FACS, Francesco Porpiglia, MD

9:00–9:10  Strategies to Manage Trifecta In Robotic Prostate Cancer Surgery  David Lee, MD
9:10–9:20  Robot Assisted Partial Prostatectomy  Inderbir Gill, MD
9:20–9:30  3D Imaging and Treatment Planning  Francesco Porpiglia, MD
9:30–9:40  Newer Techniques in RARP/Fluorescent Guided Surgery  Ashok Hemal, MD
9:40–9:50  Pelvic LND for Prostate Cancer – Worth the Full Effort or Skip?  John Davis, MD, FACS
9:50–10:00  Extraperitoneal Radical Prostatectomy  Jean Joseph, MD
10:00–10:10  Perineal Radical Prostatectomy  Jihad Kaouk, MD
10:10–10:20  “Art” of Radical Prostatectomy  Fabrizio Dal Moro, MD
10:20–10:40  Journey of Robotic Surgery  Mani Menon, MD
10:40–11:00  BREAK / VISIT EXHIBITS

SESSION II  TREATING LOCALIZED DISEASE
Moderator: Rakesh Kapoor, MD

11:00–11:10  Active Surveillance  Deepak Kapoor, MD
11:10–11:20  Brachytherapy  Richard Stock, MD
11:20–11:30  Focal Therapy  Aaron Katz, MD, FACS
11:30–11:40  Radical Prostatectomy  Prasanna Sooriakumaran, MD, PhD
11:40–11:50  Radiotherapy  Michael Zelefsky, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50–12:05</td>
<td>DEBATE: Best Method to Treat High Risk Cancer</td>
<td>Francesco Porpiglia, MD</td>
</tr>
<tr>
<td>12:05–12:20</td>
<td>Radiotherapy</td>
<td>Michael Zelefsky, MD</td>
</tr>
<tr>
<td>12:20–12:25</td>
<td>DEBATE: Best Method to Treat Low Risk Cancer</td>
<td>Ketan K. Badani, MD</td>
</tr>
<tr>
<td>1:20–1:50</td>
<td>Anatomical Foundations of RP – Nerve Sparing</td>
<td>Ash Tewari, MBBS, MCh</td>
</tr>
<tr>
<td>1:50–2:50</td>
<td>Live Surgery</td>
<td>Mani Menon, MD</td>
</tr>
<tr>
<td></td>
<td>Panel: Craig Nobert, MD, Prasanna Sooriakumaran, MD, PhD, James Porter, MD, Jean Joseph, MD</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION III**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:05–2:15</td>
<td>Disseminated Tumor Cells at the Time of Radical Prostatectomy – What is the Real Incidence?</td>
<td>Kenneth Pienta, MD</td>
</tr>
<tr>
<td>2:30–2:45</td>
<td>PTEN Signaling and Metabolism</td>
<td>Eric Schadt, PhD</td>
</tr>
<tr>
<td>2:45–3:00</td>
<td>DNA Damage and Repair</td>
<td>Philip Kantoff, MD</td>
</tr>
<tr>
<td>3:00–3:15</td>
<td>Gene-Oncogene Interactions</td>
<td>Carlos Cordon-Cardo, MD, PhD</td>
</tr>
<tr>
<td>3:15–3:30</td>
<td>Prostate Cancer Heterogeneity</td>
<td>Ganesha Palapattu, MD</td>
</tr>
<tr>
<td>3:30–3:45</td>
<td>Racial Disparities In Prostate Cancer</td>
<td>Isaac Powell, MD</td>
</tr>
<tr>
<td>3:45–4:00</td>
<td>ADT and Castration Resistance</td>
<td>William Oh, MD</td>
</tr>
<tr>
<td>4:00–4:15</td>
<td>Chemotherapy in Prostate Cancer</td>
<td>Matthew Galsky, MD</td>
</tr>
<tr>
<td>4:15–4:30</td>
<td>PSMA Targeted Therapy</td>
<td>Daniel Petrylak, MD</td>
</tr>
<tr>
<td>4:30–4:45</td>
<td>Treatment of Primary Lesion in Metastatic Prostate Cancer</td>
<td>Brian Francis Chapin, MD</td>
</tr>
<tr>
<td>4:45–5:00</td>
<td>Multimodal Treatment Paradigm in Early Metastatic Prostate Cancer</td>
<td>Vincent Laudone, MD</td>
</tr>
<tr>
<td>5:00–5:15</td>
<td>Novel Approaches to Bone Metastasis in Prostate Cancer</td>
<td>Alice Levine, MD</td>
</tr>
<tr>
<td>5:15–5:30</td>
<td>Treatment of Primary Lesion in Metastatic Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td>5:30–5:45</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

The following speakers will participate in sessions separate from the CME-accredited activity. These sessions will not be accredited for CME.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:50–6:00</td>
<td>Research Discovery and Preclinical Development of Immunotherapy Drugs</td>
<td>Robert Stein, MD, PhD</td>
</tr>
<tr>
<td>6:00–6:10</td>
<td>Drug Discovery and Development Of XTANDI: Lessons Learned from the Journey</td>
<td>Lynn Seeley</td>
</tr>
<tr>
<td>6:10–6:20</td>
<td>Role of Prostate Cancer Foundation In Supporting Prostate Cancer Research</td>
<td>Jonathan Simons, MD</td>
</tr>
<tr>
<td>6:20–6:30</td>
<td>Integration of Imaging &amp; Robotics: Robotic Platform of 21st Century</td>
<td>Gary Guthart, PhD</td>
</tr>
</tbody>
</table>

**BREAKOUT ROOM – ANNENBERG 5-205**

**SESSION I**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:40–1:55</td>
<td>Role of RT for High Risk Disease</td>
<td>Richard Stock, MD</td>
</tr>
<tr>
<td>1:55–2:10</td>
<td>Role of ADT with RT</td>
<td>Michael Zelefsky, MD</td>
</tr>
<tr>
<td>2:10–2:25</td>
<td>Role of PSMA In Locally Advanced Disease</td>
<td>Markus Hohenfellner, MD</td>
</tr>
<tr>
<td>2:25–2:35</td>
<td>Cyberknife</td>
<td>Jonathan Haas, MD</td>
</tr>
<tr>
<td>2:35–2:45</td>
<td>IMRT</td>
<td>Shawn Zimberg, MD</td>
</tr>
<tr>
<td>2:45–3:05</td>
<td>DEBATE: Cyberknife vs. IMRT</td>
<td>Richard Stock, MD, Jonathan Haas, MD, Shawn Zimberg, MD</td>
</tr>
</tbody>
</table>

**SESSION II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00–2:15</td>
<td>Disseminated Tumor Cells at the Time of Radical Prostatectomy – What is the Real Incidence?</td>
<td>Kenneth Pienta, MD</td>
</tr>
<tr>
<td>2:30–2:45</td>
<td>PTEN Signaling and Metabolism</td>
<td>Eric Schadt, PhD</td>
</tr>
<tr>
<td>2:45–3:00</td>
<td>DNA Damage and Repair</td>
<td>Philip Kantoff, MD</td>
</tr>
<tr>
<td>3:00–3:15</td>
<td>Gene-Oncogene Interactions</td>
<td>Carlos Cordon-Cardo, MD, PhD</td>
</tr>
<tr>
<td>3:15–3:30</td>
<td>Prostate Cancer Heterogeneity</td>
<td>Ganesha Palapattu, MD</td>
</tr>
<tr>
<td>3:30–3:45</td>
<td>Racial Disparities In Prostate Cancer</td>
<td>Isaac Powell, MD</td>
</tr>
<tr>
<td>3:45–4:00</td>
<td>ADT and Castration Resistance</td>
<td>William Oh, MD</td>
</tr>
<tr>
<td>4:00–4:15</td>
<td>Chemotherapy in Prostate Cancer</td>
<td>Matthew Galsky, MD</td>
</tr>
<tr>
<td>4:15–4:30</td>
<td>PSMA Targeted Therapy</td>
<td>Daniel Petrylak, MD</td>
</tr>
<tr>
<td>4:30–4:45</td>
<td>Treatment of Primary Lesion in Metastatic Prostate Cancer</td>
<td>Brian Francis Chapin, MD</td>
</tr>
<tr>
<td>4:45–5:00</td>
<td>Multimodal Treatment Paradigm in Early Metastatic Prostate Cancer</td>
<td>Vincent Laudone, MD</td>
</tr>
<tr>
<td>5:00–5:15</td>
<td>Novel Approaches to Bone Metastasis in Prostate Cancer</td>
<td>Alice Levine, MD</td>
</tr>
<tr>
<td>5:15–5:30</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

The following speakers will participate in sessions separate from the CME-accredited activity. These sessions will not be accredited for CME.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:50–6:00</td>
<td>Research Discovery and Preclinical Development of Immunotherapy Drugs</td>
<td>Robert Stein, MD, PhD</td>
</tr>
<tr>
<td>6:00–6:10</td>
<td>Drug Discovery and Development Of XTANDI: Lessons Learned from the Journey</td>
<td>Lynn Seeley</td>
</tr>
<tr>
<td>6:10–6:20</td>
<td>Role of Prostate Cancer Foundation In Supporting Prostate Cancer Research</td>
<td>Jonathan Simons, MD</td>
</tr>
<tr>
<td>6:20–6:30</td>
<td>Integration of Imaging &amp; Robotics: Robotic Platform of 21st Century</td>
<td>Gary Guthart, PhD</td>
</tr>
</tbody>
</table>
FRIDAY, SEPTEMBER 8th

3:05–3:15  Neoadjuvant Systemic Therapy  
Brian Francis Chapin, MD

3:15–3:35  BREAK / VISIT EXHIBITS

SESSION II

MORBIDITY AND QUALITY OF LIFE

Moderator: Victor Nitti, MD

3:35–3:45  Penile Rehabilitation and Pharmacologic Treatment of ED  
Natan Bar-Chama, MD

3:45–4:05  Penile Implantation Post-RP  
Robert Valenzuela, MD

4:05–4:15  Urethral Stricture Management  
Rajveer Purohit, MD, FACS, MPH

4:15–4:25  Surgical Factors Influencing Early Continence Recovery  
Vincenzo Ficarra, MD, PhD

4:25–4:35  Post-RP Incontinence Management  
Victor Nitti, MD

4:35–4:55  DEBATE: Post-prostatectomy Incontinence: PFMT vs. Early Sling/AUS  
Moderator: Victor Nitti, MD  
PFMT: Steven A. Kaplan, MD  
Early Sling/AUS: Neil Grafstein, MD

4:55–5:05  Treatment of LUTS Following RALP & RT  
Jerry Blaivas, MD

5:05–5:15  Qol. and Lifestyle Changes – General Health Perspective  
Jeffrey Mechanick, MD

5:15–5:25  Qol. and Lifestyle Changes – Urology Perspective  
Philippa Cheetham, MD

5:25–5:35  Complications in Robotic Surgery Distant from the Surgical Site  
Daniel Gainsburg, MD

5:35–5:45  Peri-operative Safety Initiatives  
Amanda Rhee, MD

Join us for a gala dinner on Friday, September 8th from 7–10pm at the NYC landmark Pierre Hotel. Live and silent auctions.
For more information and to RSVP, contact Carrie Brennan at caroline.brennan@mountsinai.org

AGENDA

SATURDAY, SEPTEMBER 9th

STERN AUDITORIUM

SESSION I

KIDNEY CANCER I

Moderator: Michael A. Palese, MD, Ashok Hemal, MD

7:00–7:05  Welcome and Program Overview  
Ketan K. Badani, MD

7:05–7:20  The Changing Face of Urologic Oncologic Surgery Over 15 Years: The Impact of Robotics  
Inderbir Gill, MD

7:20–7:35  Recovery of Renal Function after Radical and Partial Nephrectomy  
Steven Campbell, MD, PhD

7:35–7:50  Adjuvant Therapy in Renal Cell Carcinoma Where Are We in 2017?  
Robert Uzzo, MD, FACS

7:50–8:15  DEBATE: Small Renal Mass Biopsy  
Pro: Jaime Landman, MD  
Con: Ronney Abaza, MD

8:15–8:40  Panel Discussion on Management of Renal Cancer  
Presenter: Chandru Sundaram, MD  
Panel: Jihad Kaouk, MD, Jaime Landman, MD, Ketan K. Badani, MD, Rene Sotelo, MD

8:40–9:05  DEBATE: Transperitoneal vs. Retroperitoneal Partial Nephrectomy  
Transperitoneal: Jihad Kaouk, MD  
Retroperitoneal: James Porter, MD

9:05–9:15  BREAK / VISIT EXHIBITS

SESSION II

KIDNEY CANCER II

Moderators: Inderbir Gill, MD, Chandru Sundaram, MD

9:15–9:30  Tips and Tricks of Urinary Reconstruction  
Daniel Eun, MD

9:30–9:55  DEBATE: Partial vs. Radical Nephrectomy for cT1b and cT2 Renal Masses with Normal Kidney Function  
Pro: Steven Campbell, MD, PhD  
Con: Robert Uzzo, MD
AGENDA

SATURDAY, SEPTEMBER 9th continued

9:55–10:05  Update on Randomized Clinical Trial of the Use of Amniotic Membrane on Renal Preservation after Partial Nephrectomy  Ketan K. Badani, MD

10:05–10:30  Challenging Cases and Management Strategies  Moderator: Rene Sotelo, MD  Panel: Ketan K. Badani, MD, Daniel Eun, MD, Francesco Porpiglia, MD, James Porter, MD

10:30–11:50  Live Surgery  Surgeon: Ketan K. Badani, MD  Panel: Inderbir Gill, MD, Aneesh Srivastava, MD, Daniel Eun, MD, Ashok Hemal, MD

11:50–12:00  Complex Robotic Radical Nephrectomy and IVC Thrombectomy  Ronney Abaza, MD

12:00–1:00  LUNCH BREAK

SESSION III  KIDNEY CANCER III

Moderators: Nikhil Waingankar, MD, MPH, James Porter, MD

1:00–2:00  Live/Semi Live Surgery  Surgeon: Ketan K. Badani, MD  Panel: Jihad Kaouk, MD, Ronney Abaza, MD, Dipen Parekh, MD

2:00–2:10  Role of Cytoreductive Nephrectomy in the Targeted Therapy Era  Che-Kai Tsao, MD

2:10–2:25  Endourological Approach to Upper Tract Transitional Carcinoma: Past and Present  Arthur Smith, MD

2:25–2:50  DEBATE: Management of 2cm Urothelial Carcinoma of Renal Pelvis  Expert Panelist: Manoj Monga, MD  Endoscopic Treatment: Mantu Gupta, MD  Nephroureterectomy: Ashok Hemal, MD

2:50–3:00  BREAK / VISIT EXHIBITS

SESSION IV  BLADDER CANCER I

Moderators: Khurshid Guru, MD, Reza Mehrazin, MD

3:00–3:05  Welcome  Peter Wiklund, MD, PhD

3:05–3:20  Radical Cystectomy and “The Law of Small Numbers”  Mark Schoenberg, MD

3:20–3:35  Complications in Robotic Cystectomy  Rene Sotelo, MD

3:35–3:50  RAZOR Trial  Dipen Parekh, MD

3:50–4:05  ERAS Protocol  Khurshid Guru, MD

4:05–5:05  DEBATE: Urinary Diversion in Robotic Radical Cystectomy  Open: Dipen Parekh, MD  Robotic: Khurshid Guru, MD

5:05–5:30  Oncological Updates on RARC  Justin Collins, MD

5:45–6:00  Outcomes After RARC and Aiming Points for the Future  Peter Wiklund, MD, PhD

6:00–6:15  Should We Be Doing Extended LND During Radical Cystectomy  John Sfakianos, MD

6:15–6:30  Adjuvant or Neoadjuvant Chemotherapy in Bladder Cancer  Matthew Galsky, MD

6:30–6:35  Closing Remarks  Ketan K. Badani, MD

REGISTER ON-LINE:  www.mountsinaiurologycme.org

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD, PhD</td>
<td>$625</td>
</tr>
<tr>
<td>Residents/Fellows</td>
<td>$250</td>
</tr>
<tr>
<td>Nurses, PAs and Allied Health Professionals</td>
<td>$150</td>
</tr>
</tbody>
</table>

Mount Sinai faculty, residents, employees and voluntary faculty are eligible for scholarship, and must have a coupon code. Contact Carrie Brennan, Department of Urology for information @ caroline.brennan@mountsinai.org

CANCELLATION POLICY

A $50 administrative fee will be deducted from all refunds/cancellations issued. All refund and cancellation requests must be emailed to the CME Office at cme@mssm.edu by August 23, 2017. No refunds will be made after this date or for “no-shows.”
MOUNT SINAI FACULTY

COURSE DIRECTOR
Ash Tewari, MBBS, MCh

CO–DIRECTOR
Ketan K. Badani, MD

ASSOCIATE DIRECTORS
Nina Bhardwaj, MD, PhD
Carlos Cordon-Cardo, MD, PhD
William Oh, MD

SITE DIRECTORS
Mantu Gupta, MD
Michael A. Palese, MD

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI FACULTY

Natan Bar-Chama, MD
Jerry Blaivas, MD
Phiippa Cheetham, MD
Josep Domingo-Domenech, MD, PhD
Michael J. Droller, MD
Daniel Gainsburg, MD
Matthew Galsky, MD
Sacha Gnjatic, PhD
INVITED FACULTY

Ronney Abaza, MD
Ohio Health Dublin Methodist Hospital
Dublin, Ohio

David Albala, MD
Associated Medical Professionals
Syracuse, New York

Jeffrey Bockman, PhD
Defined Health
Florham Park, New Jersey

Thomas Ahlering, MD
UC Irvine Health
Orange, California

Thomas Bessede, MD
University Paris-Sud, INSERM,
University Paris-Saclay,
Le Kremlin Bicêtre, France

Steven Campbell, MD, PhD
Cleveland Clinic
Cleveland, Ohio

Giuseppe Carrieri, MD
University of Foggia
Foggia, Italy

Peter Carroll, MD, MPH
University of California,
San Francisco
San Francisco, California

Brian Francis Chapin, MD
MD Anderson Cancer Center
Houston, Texas

Justin Collins, MD
Karolinska Institutet
Stockholm, Sweden

Michael Cookson, MD
The University of Oklahoma
College of Medicine
Oklahoma City, Oklahoma

Fabrizio Dal Moro, MD
University of Padua
Padua, Italy

John Davis, MD, FACS
MD Anderson Cancer Center
Houston, Texas

Daniel Eun, MD
Lewis Katz School of Medicine at
Temple University
Philadelphia, Pennsylvania

Vincenzo Ficarra, MD, PhD
University of Udine
Udine, Italy

Inderbir Gill, MD
Keck School of Medicine of USC
Los Angeles, California

Leonard Gomella, MD
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania

Nate Gross, MD
Doximity
San Francisco, California
INVITED FACULTY

James Gulley, MD, PhD
National Cancer Institute, NIH
Bethesda, Maryland

Khurshid Guru, MD
Roswell Park Cancer Institute
Buffalo, New York

Jonathan Haas, MD
Winthrop University Hospital
Mineola, New York

Alexander Haese, MD
The Martini-Clinic Prostate Cancer Center
University Clinic Eppendorf
Hamburg, Germany

Simon Hall, MD
Northwell Health
New Hyde Park, New York

Axel Heidenreich, MD
Universitätsklinikum Kölner Zertifiziertes
Cologne, Germany

Ashok Hemal, MD
Wake Forest Baptist Health
Winston-Salem, North Carolina

Michael Herman, MD
Weill Cornell Medicine
New York, New York

Markus Hohenfellner, MD
University of Heidelberg
Heidelberg, Germany

Jim Hu, MD, MPH
Weill Cornell Medicine
New York, New York

Jean Joseph, MD
University of Rochester
Wilmot Cancer Institute
Rochester, New York

Philip Kantoff, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Jihad Kaouk, MD
Cleveland Clinic
Cleveland, Ohio

Rakesh Kapoor, MBBS, MCh
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, India

Aaron Katz, MD, FACS
Winthrop University Hospital
Mineola, New York

Eric Klein, MD
Cleveland Clinic
Cleveland, Ohio

Badrinath Konety, MD, MBA
University of Minnesota
Minneapolis, Minnesota

Jaime Landman, MD
UC Irvine Health
Orange, California
INVITED FACULTY

David Lee, MD
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Herbert Lepor, MD
NYU Langone Health
New York, New York

John Libertino, MD
Emerson Hospital
Concord, Massachusetts

Manoj Monga, MD
Cleveland Clinic
Cleveland, Ohio

Victor Nitti, MD
NYU Langone Health
New York, New York

Mani Menon, MD
Henry Ford Health System
Detroit, Michigan

Vipul Patel, MD
Florida Hospital Global Robotics Institute
Celebration, Florida

Kenneth Pienta, MD
John Hopkins Medicine
James Buchanan Brady Urological Institute
Baltimore, Maryland

Dipen Parekh, MD
University of Miami Miller School of Medicine
Coral Gables, Florida

Daniel Petrylak, MD
Yale School of Medicine
New Haven, Connecticut

Manoj Monga, MD
NYU Langone Health
New York, New York

Christopher Porter, MD, FACS
Virginia Mason Medical Center
Seattle, Washington

Christopher Porter, MD, FACS
Virginia Mason Medical Center
Seattle, Washington

Isaac Powell, MD
Wayne State University Karmanos Cancer Institute
Detroit, Michigan

James Porter, MD
Swedish Urology Group
Seattle, Washington

Mark Schoenberg, MD
Albert Einstein College of Medicine Montefiore Medical Center
Bronx, New York

Fritz Schröder, MD
Erasmus University Medical Center
Rotterdam, Netherlands

Peter Schulam, MD, PhD
Yale School of Medicine
New Haven, Connecticut
INVITED FACULTY

Ankur Singh, PhD
Cornell University
Ithaca, New York

Prasanna Sooriakumaran, MD, PhD
University College Hospital
London, United Kingdom

Aneesh Srivastava, MD
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow, India

Atsushi Takenaka, MD
Tottori University Faculty of Medicine
Tottori, Japan

Arnauld Villers MD, PhD
University of Lille
Lille, France

Peter Wiklund, MD, PhD
Karolinska Institutet
Sweden

Michael Zelefsky, MD
Memorial Sloan Kettering Cancer Center
New York, New York

The following speakers will participate in sessions separate from the CME-accredited activity. These sessions will not be accredited for CME.

Gary Guthart, PhD
Intuitive Surgical, Inc.
Sunnyvale, California

Lynn Seely, MD
Myovant Sciences
Brisbane, California

Jonathan Simons, MD
Milken Institute
Santa Monica, California

Robert Stein, MD, PhD
Agenusbio
Lexington, Massachusetts

ORGANIZERS
Alp Tuna Bek sac, MD
Michael J. Droller, MD

Steven A. Kaplan, MD
Reza Mehrazin, MD

Carl Olsson, MD
John Sfakianos, MD

Susan F. Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, New York

Rene Sotelo, MD
Keck School of Medicine of USC
Los Angeles, California

Chandru Sundaram, MD
Indiana School of Medicine
Indianapolis, Indiana

Robert Uzzo, MD, FACS
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Patrick Walsh, MD
John Hopkins Medicine
James Buchanan Brady Urological Institute
Baltimore, Maryland

Jörn Witt, MD
St. Antonius-Hospital
Utrecht, Netherlands

Gary Guthart, PhD
Intuitive Surgical, Inc.
Sunnyvale, California

Lynn Seely, MD
Myovant Sciences
Brisbane, California

Robert Stein, MD, PhD
Agenusbio
Lexington, Massachusetts
2ND International Prostate Cancer Symposium
and
Inaugural World Congress of Urologic Oncology

SEPTEMBER 6-9, 2017
Mount Sinai Hospital
Stern Auditorium

REGISTER ON-LINE: www.mountsinaiurologycme.org